Politics ❯ Government Policy
Pharmaceutical Industry FTC Actions Negotiation Economic Impact Pharmaceutical Regulation US Government Healthcare Access Healthcare Legislation Consumer Access
The cash-plus-CVR deal followed FTC concerns over Novo Nordisk’s bid, setting expectations for near-term dilution.
